These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 14506151

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix.
    Cohen Y, Singer G, Lavie O, Dong SM, Beller U, Sidransky D.
    Clin Cancer Res; 2003 Aug 01; 9(8):2981-4. PubMed ID: 12912945
    [Abstract] [Full Text] [Related]

  • 3. Promoter methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and neck squamous cell carcinoma: pharmacological genome demethylation reduces proliferation of head and neck squamous carcinoma cells.
    Koutsimpelas D, Pongsapich W, Heinrich U, Mann S, Mann WJ, Brieger J.
    Oncol Rep; 2012 Apr 01; 27(4):1135-41. PubMed ID: 22246327
    [Abstract] [Full Text] [Related]

  • 4. Epigenetic inactivation of RASSF1A candidate tumor suppressor gene at 3p21.3 in brain tumors.
    Horiguchi K, Tomizawa Y, Tosaka M, Ishiuchi S, Kurihara H, Mori M, Saito N.
    Oncogene; 2003 Oct 30; 22(49):7862-5. PubMed ID: 14586413
    [Abstract] [Full Text] [Related]

  • 5. Promoter hypermethylation of RASSF1A in esophageal squamous cell carcinoma.
    Kuroki T, Trapasso F, Yendamuri S, Matsuyama A, Alder H, Mori M, Croce CM.
    Clin Cancer Res; 2003 Apr 30; 9(4):1441-5. PubMed ID: 12684417
    [Abstract] [Full Text] [Related]

  • 6. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma.
    Lee MG, Kim HY, Byun DS, Lee SJ, Lee CH, Kim JI, Chang SG, Chi SG.
    Cancer Res; 2001 Sep 15; 61(18):6688-92. PubMed ID: 11559536
    [Abstract] [Full Text] [Related]

  • 7. Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma.
    Byun DS, Lee MG, Chae KS, Ryu BG, Chi SG.
    Cancer Res; 2001 Oct 01; 61(19):7034-8. PubMed ID: 11585730
    [Abstract] [Full Text] [Related]

  • 8. The candidate tumor suppressor gene BLU, located at the commonly deleted region 3p21.3, is an E2F-regulated, stress-responsive gene and inactivated by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma.
    Qiu GH, Tan LK, Loh KS, Lim CY, Srivastava G, Tsai ST, Tsao SW, Tao Q.
    Oncogene; 2004 Jun 10; 23(27):4793-806. PubMed ID: 15122337
    [Abstract] [Full Text] [Related]

  • 9. Aberrant promoter hypermethylation and silencing of the critical 3p21 tumour suppressor gene, RASSF1A, in Chinese oesophageal squamous cell carcinoma.
    Wong ML, Tao Q, Fu L, Wong KY, Qiu GH, Law FB, Tin PC, Cheung WL, Lee PY, Tang JC, Tsao GS, Lam KY, Law S, Wong J, Srivastava G.
    Int J Oncol; 2006 Mar 10; 28(3):767-73. PubMed ID: 16465383
    [Abstract] [Full Text] [Related]

  • 10. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma.
    Tomizawa Y, Kohno T, Kondo H, Otsuka A, Nishioka M, Niki T, Yamada T, Maeshima A, Yoshimura K, Saito R, Minna JD, Yokota J.
    Clin Cancer Res; 2002 Jul 10; 8(7):2362-8. PubMed ID: 12114441
    [Abstract] [Full Text] [Related]

  • 11. Critical role of deltaDNMT3B4/2 in regulating RASSF1A promoter-specific DNA methylation in non-small cell lung cancer.
    Wang SH, Liu NH, Wang J, Bai H, Mao L.
    Chin Med J (Engl); 2008 Sep 05; 121(17):1712-21. PubMed ID: 19024105
    [Abstract] [Full Text] [Related]

  • 12. Deleted in colorectal cancer is a putative conditional tumor-suppressor gene inactivated by promoter hypermethylation in head and neck squamous cell carcinoma.
    Carvalho AL, Chuang A, Jiang WW, Lee J, Begum S, Poeta L, Zhao M, Jerónimo C, Henrique R, Nayak CS, Park HL, Brait MR, Liu C, Zhou S, Koch W, Fazio VM, Ratovitski E, Trink B, Westra W, Sidransky D, Moon CS, Califano JA.
    Cancer Res; 2006 Oct 01; 66(19):9401-7. PubMed ID: 17018594
    [Abstract] [Full Text] [Related]

  • 13. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
    Schagdarsurengin U, Gimm O, Hoang-Vu C, Dralle H, Pfeifer GP, Dammann R.
    Cancer Res; 2002 Jul 01; 62(13):3698-701. PubMed ID: 12097277
    [Abstract] [Full Text] [Related]

  • 14. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.
    Zhang YJ, Ahsan H, Chen Y, Lunn RM, Wang LY, Chen SY, Lee PH, Chen CJ, Santella RM.
    Mol Carcinog; 2002 Oct 01; 35(2):85-92. PubMed ID: 12325038
    [Abstract] [Full Text] [Related]

  • 15. Epigenetic inactivation of TSLC1 gene in nasopharyngeal carcinoma.
    Hui AB, Lo KW, Kwong J, Lam EC, Chan SY, Chow LS, Chan AS, Teo PM, Huang DP.
    Mol Carcinog; 2003 Dec 01; 38(4):170-8. PubMed ID: 14639656
    [Abstract] [Full Text] [Related]

  • 16. Re-expression of RASSF1A by 5-Aza-CdR induced demethylation of the promoter region in human biliary tract carcinoma cells.
    Zuo S, Chen Y, Xu L, Tang Q, Zou S.
    J Huazhong Univ Sci Technolog Med Sci; 2007 Jun 01; 27(3):281-4. PubMed ID: 17641842
    [Abstract] [Full Text] [Related]

  • 17. Inactivation of the RASSF1A in osteosarcoma.
    Lim S, Yang MH, Park JH, Nojima T, Hashimoto H, Unni KK, Park YK.
    Oncol Rep; 2003 Jun 01; 10(4):897-901. PubMed ID: 12792742
    [Abstract] [Full Text] [Related]

  • 18. Hypermethylation-modulated downregulation of RASSF1A expression is associated with the progression of esophageal cancer.
    Mao WM, Li P, Zheng QQ, Wang CC, Ge MH, Hu FJ, Fang XH, Dong ZM, Ling ZQ.
    Arch Med Res; 2011 Apr 01; 42(3):182-8. PubMed ID: 21722812
    [Abstract] [Full Text] [Related]

  • 19. Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers.
    Agathanggelou A, Dallol A, Zöchbauer-Müller S, Morrissey C, Honorio S, Hesson L, Martinsson T, Fong KM, Kuo MJ, Yuen PW, Maher ER, Minna JD, Latif F.
    Oncogene; 2003 Mar 13; 22(10):1580-8. PubMed ID: 12629521
    [Abstract] [Full Text] [Related]

  • 20. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours.
    Astuti D, Agathanggelou A, Honorio S, Dallol A, Martinsson T, Kogner P, Cummins C, Neumann HP, Voutilainen R, Dahia P, Eng C, Maher ER, Latif F.
    Oncogene; 2001 Nov 08; 20(51):7573-7. PubMed ID: 11709729
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.